Daniel Ricklin

15.5k total citations · 3 hit papers
143 papers, 12.1k citations indexed

About

Daniel Ricklin is a scholar working on Immunology, Hematology and Molecular Biology. According to data from OpenAlex, Daniel Ricklin has authored 143 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Immunology, 42 papers in Hematology and 36 papers in Molecular Biology. Recurrent topics in Daniel Ricklin's work include Complement system in diseases (96 papers), Renal Diseases and Glomerulopathies (25 papers) and Monoclonal and Polyclonal Antibodies Research (23 papers). Daniel Ricklin is often cited by papers focused on Complement system in diseases (96 papers), Renal Diseases and Glomerulopathies (25 papers) and Monoclonal and Polyclonal Antibodies Research (23 papers). Daniel Ricklin collaborates with scholars based in United States, Switzerland and Germany. Daniel Ricklin's co-authors include John D. Lambris, George Hajishengallis, Kun Yang, Edimara S. Reis, Dimitrios C. Mastellos, Brian V. Geisbrecht, Piet Gros, Christoph Q. Schmidt, Jin Wu and Αποστολία Τζέκου and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Daniel Ricklin

137 papers receiving 11.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Complement: a key system for immune surveillance and homeostasis

2010 2.8k citations Daniel Ricklin, George Hajishengallis et al. Nature Immunology profile →
Complement evasion by human pathogens

2008 573 citations John D. Lambris, Daniel Ricklin et al. profile →
Complement in disease: a defence system turning offensive

2016 410 citations Daniel Ricklin, Edimara S. Reis et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Ricklin United States	49	7.9k	2.5k	2.3k	1.8k	1.4k	143	12.1k
Anna M. Blom Sweden	65	6.9k 0.9×	2.9k 1.2×	1.9k 0.8×	1.4k 0.8×	1.5k 1.1×	357	13.8k
Seppo Meri Finland	75	9.0k 1.1×	3.0k 1.2×	2.5k 1.1×	1.6k 0.9×	2.0k 1.4×	389	17.4k
Marina Botto United Kingdom	67	10.0k 1.3×	2.9k 1.2×	1.6k 0.7×	1.7k 0.9×	1.2k 0.9×	193	14.8k
V. Michael Holers United States	85	13.5k 1.7×	4.2k 1.7×	3.7k 1.6×	2.8k 1.6×	988 0.7×	434	24.7k
John Atkinson United States	59	5.2k 0.7×	2.1k 0.8×	1.3k 0.6×	538 0.3×	1.2k 0.9×	160	9.6k
Thomas J. Schall United States	75	15.7k 2.0×	4.3k 1.8×	1.1k 0.5×	760 0.4×	1.6k 1.2×	185	25.8k
Mohamed R. Daha Netherlands	78	13.7k 1.7×	4.1k 1.7×	3.6k 1.6×	5.3k 3.0×	1.2k 0.9×	540	24.3k
Douglas T. Fearon United States	76	15.2k 1.9×	5.4k 2.2×	3.0k 1.3×	936 0.5×	945 0.7×	178	24.5k
Peter F. Zipfel Germany	86	13.0k 1.7×	3.8k 1.6×	4.4k 1.9×	4.6k 2.6×	4.4k 3.1×	386	22.6k
Klaus T. Preissner Germany	71	4.8k 0.6×	6.8k 2.8×	4.4k 1.9×	377 0.2×	1.1k 0.8×	317	19.2k

Countries citing papers authored by Daniel Ricklin

Since Specialization

Citations

This map shows the geographic impact of Daniel Ricklin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Ricklin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Ricklin more than expected).

Fields of papers citing papers by Daniel Ricklin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Ricklin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Ricklin. The network helps show where Daniel Ricklin may publish in the future.

Co-authorship network of co-authors of Daniel Ricklin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Ricklin. A scholar is included among the top collaborators of Daniel Ricklin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Ricklin. Daniel Ricklin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rabbani, Said, et al.. (2025). The power of fusion: Tuning pharmacokinetic and pharmacodynamic properties of complement-modulating peptides and proteins via antibody engineering. Immunobiology. 230(4). 152993–152993.

Rabbani, Said, et al.. (2025). Determining Ligand Binding and Specificity Within the β2-Integrin Family with a Novel Assay Platform. Biomolecules. 15(2). 238–238.

Seibert, Isabell, et al.. (2025). Erlotinib—A substrate and inhibitor of OATP2B1: pharmacokinetics and CYP3A-mediated metabolism in rSlco2b1−/− and SLCO2B1+/+ rats. Drug Metabolism and Disposition. 53(5). 100069–100069.

Zhao, Haijie, et al.. (2025). A versatile screening platform to guide applications for the FH-recruiting peptide 5C6 on non-self surfaces. Immunobiology. 230(4). 153074–153074.

Ricklin, Daniel. (2024). Complement‐targeted therapeutics: Are we there yet, or just getting started?. European Journal of Immunology. 54(12). e2350816–e2350816. 13 indexed citations

Brecht, Karin, et al.. (2024). Humanization of SLCO2B1 in Rats Increases rCYP3A1 Protein Expression but Not the Metabolism of Erlotinib to OSI-420. Journal of Pharmacology and Experimental Therapeutics. 389(1). 87–95. 3 indexed citations

Lamers, Christina, Daniel Ricklin, & John D. Lambris. (2023). Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery. American Journal of Hematology. 98(S4). S82–S89. 18 indexed citations

Seibert, Isabell, et al.. (2023). Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method. Journal of Pharmaceutical and Biomedical Analysis. 236. 115716–115716. 2 indexed citations

Lamers, Christina, Martin Smieško, Georgia Sfyroera, et al.. (2022). Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors. Nature Communications. 13(1). 5519–5519. 23 indexed citations

10.

Kuipers, Annemarie, Jürgen Strasser, Maartje Ruyken, et al.. (2021). C1q binding to surface-bound IgG is stabilized by C1r ₂ s ₂ proteases. Proceedings of the National Academy of Sciences. 118(26). 39 indexed citations

11.

Tomašič, Tihomir, Žiga Jakopin, Hakon Leffler, et al.. (2021). Selective Monovalent Galectin‐8 Ligands Based on 3‐Lactoylgalactoside. ChemMedChem. 17(3). e202100514–e202100514. 7 indexed citations

12.

Harris, Claire L., et al.. (2018). Developments in anti-complement therapy; from disease to clinical trial. Molecular Immunology. 102. 89–119. 66 indexed citations

13.

Wang, Hongbin, Daniel Ricklin, & John D. Lambris. (2017). Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proceedings of the National Academy of Sciences. 114(41). 10948–10953. 84 indexed citations

14.

Hajishengallis, George, Edimara S. Reis, Dimitrios C. Mastellos, Daniel Ricklin, & John D. Lambris. (2017). Novel mechanisms and functions of complement. Nature Immunology. 18(12). 1288–1298. 350 indexed citations

15.

Forneris, Federico, Jin Wu, Daniel Ricklin, et al.. (2016). Regulators of complement activity mediate inhibitory mechanisms through a common C3b‐binding mode. The EMBO Journal. 35(10). 1133–1149. 88 indexed citations

16.

Yuan, Xiaopeng, Xiang Chen, Xuhua Zhang, et al.. (2016). Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. Cancer Immunology Immunotherapy. 66(3). 367–378. 12 indexed citations

17.

Mastellos, Dimitrios C., Despina Yancopoulou, Petros Kokkinos, et al.. (2015). Compstatin: a C3‐targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation. 45(4). 423–440. 170 indexed citations

18.

Yang, Kun, Ashok Reddy Dinasarapu, Edimara S. Reis, et al.. (2013). CMAP: Complement Map Database. Bioinformatics. 29(14). 1832–1833. 31 indexed citations

19.

Forneris, Federico, Daniel Ricklin, Jiawang Wu, et al.. (2011). Complement convertase formation based on the structures of C3b in complex with factors B and D. Acta Crystallographica Section A Foundations of Crystallography. 67(a1). C23–C24. 1 indexed citations

20.

Magotti, Paola, Daniel Ricklin, Hongchang Qu, et al.. (2009). Structure‐kinetic relationship analysis of the therapeutic complement inhibitor compstatin. Journal of Molecular Recognition. 22(6). 495–505. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact